The estrogen patch shortage, explained: what to use instead

How bad is the estrogen patch shortage right now?

Worse than when it started, and broader than the U.S. By late June 2026, CNBC reported that all five American estradiol-patch manufacturers were producing at full capacity and still could not meet demand, with the squeeze described as a worldwide problem rather than a purely American one. A survey of roughly 8,000 women across 49 states found about half were struggling to fill their estradiol patch, a scale that turns "my pharmacy is out" into a national access problem. On ASHP's drug-shortage tracker, manufacturer recovery estimates for several high-volume patches, Amneal's Dotti, Viatris's Lyllana, and Noven's Vivelle-Dot, run into late 2026. Through all of it, the FDA has declined to declare a formal shortage, which keeps some supply-management tools (like eased importation or compounding allowances) off the table.

Sources: CNBC, June 26, 2026 (full-capacity manufacturers, worldwide scope, and the ~8,000-woman patch-access survey); ASHP drug-shortage tracker (estradiol transdermal system, id 1206) (product-level backorder estimates); ongoing coverage via NBC News and NPR, March 2026.

Is there an estrogen patch shortage in 2026?

It depends who you ask, and that gap is the whole story. ASHP began listing estradiol transdermal patches as in shortage in January 2026, and by May its list had grown to more than a dozen brands and dosages. ASHP's data is reported directly by pharmacists, physicians, nurses, and patients. The FDA, which only designates a shortage when supply fails to meet a formal demand threshold, has not added estradiol patches to its database. FDA Commissioner Dr. Marty Makary said the November 2025 black-box-warning removal "prompted a tremendous increase in demand… but not enough to cause a shortage," calling it "something to manage." So the accurate framing is not "the FDA denies a problem." It is that the regulator has not formally designated a shortage while front-line pharmacies and patients are clearly struggling to fill prescriptions.

Source: NBC News, May 10, 2026 (FDA Commissioner Makary quotes; ASHP estradiol transdermal system shortage list).

Why isn't the estradiol patch on the FDA shortage list?

We queried openFDA, the FDA's official programmatic interface to its own drug shortage database, on August 2, 2026. The database held 1,636 shortage records and reported itself last updated August 1, 2026. We searched estradiol four ways: free text, generic name, active substance, and the pharmacologic class "estrogen". All four came back "No matches found". To rule out a broken query, we ran the same query shape against progesterone and bupivacaine; both returned live shortage records, so the database does cover menopause hormones. As of that check, the FDA's own shortage database listed no estradiol product of any kind, patch or otherwise.

The disagreement between the two lists is structural. ASHP entries are reported directly by pharmacists, physicians, nurses and patients. The FDA designates a shortage only when supply fails a formal demand threshold.

If you are standing at a pharmacy counter, the gap reads like this. The FDA has not formally designated an estradiol shortage. That is a statement about a threshold, and it tells you nothing about whether your pharmacy can fill your prescription this week. The pharmacist-reported list has carried the patches since January. Plan around the supply problem, and use the routing table further down this page to see which providers ship the non-patch forms.

Why can't I fill my estrogen patch?

A demand spike collided with limited manufacturing. In November 2025 the FDA began removing its strongest (black-box) warnings from menopausal hormone therapy products, with labeling changes approved in February 2026, and prescribing surged. By February 2026, about 5% of women aged 45-54 (one in twenty) had an estrogen-based HRT prescription, and estrogen-patch prescriptions were up 184% since 2018, including a 25.7% jump in just July 2025 to February 2026, per Truveta's analysis of 130 million+ patient records. (Reuters described the recent climb as a rough doubling since 2023.) Multiple estradiol patch products from Amneal, Zydus, Sandoz, Noven and Viatris now have doses on the ASHP shortage list, including Amneal's Dotti, one of the most-prescribed patches. Some manufacturers say they are increasing supply.

Source: Truveta, April 9, 2026 (prescription trends); manufacturer list via ASHP / NBC News / Reuters.

How long will the estrogen patch shortage last?

Nobody knows precisely, and the public estimates disagree. Anonymous industry sources told Reuters the squeeze could last up to three years, a worst case from unnamed sources, not the FDA and not a named manufacturer, but one that looks less extreme now that all five U.S. manufacturers are already at full capacity and several brands carry backorder estimates into late 2026. Named menopause experts are more measured: Mayo Clinic's Dr. Stephanie Faubion, medical director of The Menopause Society, expects supply to improve by the end of 2026 as manufacturers scale up. The honest read as of July 2026: tight through at least the end of 2026, with real uncertainty beyond that, and a worldwide supply picture rather than a purely U.S. one. We update this page as it changes.

Source: NBC News / Reuters, April 9, 2026 ("up to three years"); Dr. Faubion via NBC News, May 10, 2026.

What can I use instead of an estrogen patch?

Clinicians quoted by NBC News describe several FDA-approved routes when a patch is short. These are options to discuss with your prescriber, not recommendations:

• Switch patch brand: a different estradiol patch (or generic) may be in stock when yours isn't.
• Two lower-dose patches: combining lower strengths to reach your usual dose.
• Switch patch schedule: moving between once-weekly and twice-weekly patch types.
• Other estrogen forms: topical gel, cream, or spray; oral tablets; or a vaginal ring (which can deliver localized or systemic estrogen). Gels, creams, sprays and patches are all transdermal estrogen and clinicians quoted by NBC consider them comparable on safety, but non-patch forms are often less likely to be covered by insurance.

Two cautions worth raising with your clinician: oral estrogen carries a small added clotting risk and is generally avoided in women with a history of blood clots; and compounded "bioidentical" HRT is not an FDA-approved substitute. The Menopause Society cautions against it because of the lack of FDA oversight, and the experts quoted in the reporting did not recommend it as a first-line workaround.

Source: Dr. Stephanie Faubion (Mayo Clinic / The Menopause Society) and Dr. Lauren Streicher (Northwestern Feinberg), via NBC News, May 10, 2026.

Estradiol gel vs patch: what is the actual difference?

Divigel is a gel. Vivelle-Dot is a patch. Evamist is a spray. In FDA labeling data read through openFDA on August 2, 2026, the patch and the spray carry the same route classification, transdermal, while the gel is classed topical. That classification is regulatory. It does not tell you whether one form controls symptoms better than another, and we are not going to pretend it does.

On safety, clinicians quoted by NBC News, among them Dr. Stephanie Faubion (Mayo Clinic, The Menopause Society) and Dr. Lauren Streicher (Northwestern Feinberg), consider gels, sprays and patches comparable: all are transdermal estrogen. The practical catch is coverage. Non-patch forms are often less likely to be covered by insurance than patches, so price out the switch with your plan before you make it.

What labeling data cannot settle: how a gel compares to a patch for your dose, your skin and your history. The FDA route field says nothing about clinical interchangeability. Which form you use is your prescriber's decision. Bring the coverage question to that conversation too.

Sources: FDA-approved labeling via openFDA drug labeling (route classification, read August 2, 2026); safety comparability via NBC News, May 10, 2026.

Questions

This is general information, not medical advice. HRT is a prescription medical treatment; whether and how to switch estrogen forms depends on your health history and must be decided with a licensed clinician. HRT Picks is not a medical provider and has no role in your care. Figures on this page were verified against the primary sources cited above on July 6, 2026. The FDA shortage-database queries and the FDA route classifications shown on this page were run by us on August 2, 2026. We update the shortage status as it changes.